Sword Diagnostics of Illinois has developed a “next-generation” system to increase the sensitivity (and therefore accuracy) of diagnostic tests.
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
Clarient is launching a new breast cancer test that helps physicians assess the probability of a patient’s cancer returning.
Center have created a test that could help doctors identify which breast cancer patients need aggressive therapy. The study, published in the online version of Clinical Cancer Research, could prevent many women from undergoing unnecessary chemotherapy or radiation treatment.